

Date: 22nd June, 2022

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir/Madam,

Sub: Update on India Branded Business

With reference to the captioned matter, an update on India Branded Business is enclosed.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja Company Secretary

Encl.: A/a.



Update on India Branded Business

There has been recent reports in newspapers quoting IQVIA data about the de-growth in pharma market.

In this regard, we thought it appropriate to inform the stakeholders of the following facts for getting the right perspective.

Indian Pharmaceutical Market ("IPM") for April 22 & May 22 has shown de-growth of -9% & -6%. Whereas, Alembic Pharmaceuticals Limited ("Alembic") has shown a de-growth of -8% & -12% respectively due to Anti-infective segment having higher base in April 21 & May 21 (Second Covid wave effect) which got normalized in current year April 22 and May 22.

Alembic's Branded Business Ex-Azithromycin has shown growth of +8% & +14% in April 22 & May 22 respectively (v/s IPM de-growth of -9% and -5% ex of Azithromycin)

Alembic's speciality segments continue to show a robust momentum on the back enhanced operational momentum and strong new product launches.

